Forte Biosciences, Inc. (FBRX)Healthcare | Biotechnology | Dallas, United States | NasdaqCM
44.12 USD
+0.20
(0.455%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 43.73 -0.39 (-0.390%) ⇩ (July 13, 2026, 6:47 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:28 a.m. EDT
The recent surge to $43.92 appears to be a classic biotech 'event-driven' spike fueled by early-stage vitiligo data, but the underlying business fundamentals tell a starkly different story. The company is in a severe multi-year freefall, having lost 99.7% of its value over the last eight years with four consecutive years of negative annual returns. Despite the 'strong buy' analyst consensus and a target price of $65, these metrics are likely pricing in a binary outcome where the company survives the current clinical trials, rather than reflecting sustainable operational excellence. The balance sheet is fragile with negative free cash flow and no revenue, making it a speculative gamble rather than an investment. Furthermore, the options market is screaming caution; the sheer volume of put buying suggests smart money is expecting this rally to reverse quickly. For a long-term investor, the lack of a dividend, negative equity generation, and a decade-long price collapse make this a dangerous hold. However, for a trader willing to navigate the extreme volatility and the risk of total capital loss, the current momentum offers a high-risk, high-reward entry point if the clinical data holds up. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.367585 |
| AutoETS | 0.379122 |
| MSTL_84 | 0.388402 |
| MSTL | 0.428688 |
| MSTL_84_126 | 0.510001 |
| AutoARIMA | 0.516994 |
| MSTL_126 | 0.546873 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 8.91 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.139 |
| Excess Kurtosis | -0.11 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 903,525,312 |
| Forward P/E | -10.65 |
| Beta | 2.84 |
| Website | https://www.fortebiorx.com |
As of July 11, 2026, 4:28 a.m. EDT: Speculators are aggressively positioning for a downside correction despite the recent rally. There is massive volume in out-of-the-money puts (over 300 contracts expiring in a week vs zero calls), creating a heavy wall of resistance around the $15-$20 strikes. While some call buying exists at higher strikes ($40-$50), the overwhelming open interest and fresh volume in puts suggest traders are betting against the current spike, anticipating a sharp pullback to test lower support levels.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.465684 |
| Address1 | 3,060 Pegasus Park Drive |
| Address2 | Building 6 |
| All Time High | 6,732.375 |
| All Time Low | 4.11 |
| Ask | 51.92 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,410,760 |
| Average Daily Volume3 Month | 432,185 |
| Average Volume | 432,185 |
| Average Volume10Days | 1,410,760 |
| Beta | 2.844 |
| Bid | 31.4 |
| Bid Size | 2 |
| Book Value | 2.356 |
| City | Dallas |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 44.12 |
| Current Ratio | 2.753 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 44.365 |
| Day Low | 40.1601 |
| Display Name | Forte Biosciences |
| Dividend Date | 1,592,265,600 |
| Earnings Timestamp End | 1,755,518,400 |
| Earnings Timestamp Start | 1,754,996,340 |
| Ebitda | -76,902,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -13.262 |
| Enterprise Value | 1,019,878,272 |
| Eps Current Year | -4.01 |
| Eps Forward | -4.142 |
| Eps Trailing Twelve Months | -4.58 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 21.8339 |
| Fifty Day Average Change | 22.286098 |
| Fifty Day Average Change Percent | 1.0207108 |
| Fifty Two Week Change Percent | 346.5684 |
| Fifty Two Week High | 45.36 |
| Fifty Two Week High Change | -1.2400017 |
| Fifty Two Week High Change Percent | -0.027336897 |
| Fifty Two Week Low | 9.1 |
| Fifty Two Week Low Change | 35.019997 |
| Fifty Two Week Low Change Percent | 3.848351 |
| Fifty Two Week Range | 9.1 - 45.36 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,492,090,200,000 |
| Float Shares | 18,828,164 |
| Forward Eps | -4.142 |
| Forward P E | -10.651858 |
| Free Cashflow | -31,247,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 22 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.021370001 |
| Held Percent Institutions | 0.76593 |
| Implied Shares Outstanding | 20,478,817 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,803,200 |
| Last Split Factor | 1:25 |
| Long Business Summary | Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas. |
| Long Name | Forte Biosciences, Inc. |
| Market | us_market |
| Market Cap | 903,525,312 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_594626683 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -75,855,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 899,429,642 |
| Number Of Analyst Opinions | 4 |
| Open | 43.86 |
| Operating Cashflow | -59,335,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 310 618 6994 |
| Post Market Change | -0.3899994 |
| Post Market Change Percent | -0.8839515 |
| Post Market Price | 43.73 |
| Post Market Time | 1,783,982,828 |
| Previous Close | 43.92 |
| Price Eps Current Year | -11.002493 |
| Price Hint | 2 |
| Price To Book | 18.726656 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.49 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.200001 |
| Regular Market Change Percent | 0.455375 |
| Regular Market Day High | 44.365 |
| Regular Market Day Low | 40.1601 |
| Regular Market Day Range | 40.1601 - 44.365 |
| Regular Market Open | 43.86 |
| Regular Market Previous Close | 43.92 |
| Regular Market Price | 44.12 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 740,427 |
| Return On Assets | -0.83897 |
| Return On Equity | -1.88396 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 20,478,817 |
| Shares Percent Shares Out | 0.0924 |
| Shares Short | 1,891,440 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,367,728 |
| Short Name | Forte Biosciences, Inc. |
| Short Percent Of Float | 0.093 |
| Short Ratio | 4.55 |
| Source Interval | 15 |
| State | TX |
| Symbol | FBRX |
| Target High Price | 75.0 |
| Target Low Price | 54.0 |
| Target Mean Price | 64.75 |
| Target Median Price | 65.0 |
| Total Cash | 58,223,000 |
| Total Cash Per Share | 2.383 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.58 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 23.120825 |
| Two Hundred Day Average Change | 20.999174 |
| Two Hundred Day Average Change Percent | 0.9082364 |
| Type Disp | Equity |
| Volume | 740,427 |
| Website | https://www.fortebiorx.com |
| Zip | 75,247 |